US 11,987,643 B2
Monoclonal antibody that specifically binds to sugar chain in which terminal sialic acid residue is bonded to galactose by alpha 2,3 bond, and measurement method for sugar chain in which terminal sialic acid residue is bonded to galactose by alpha 2,3 bond
Chikara Ohyama, Hirosaki (JP); Tohru Yoneyama, Hirosaki (JP); and Kazuyuki Hamada, Oume (JP)
Assigned to Hirosaki University, Aomori (JP); and System Instruments Co. , Ltd., Tokyo (JP)
Appl. No. 17/918,042
Filed by Hirosaki University, Aomori (JP); and System Instruments Co., Ltd., Tokyo (JP)
PCT Filed Mar. 18, 2021, PCT No. PCT/JP2021/011034
§ 371(c)(1), (2) Date Oct. 10, 2022,
PCT Pub. No. WO2022/195796, PCT Pub. Date Sep. 22, 2022.
Prior Publication US 2024/0034811 A1, Feb. 1, 2024
Int. Cl. C07K 16/44 (2006.01); G01N 33/66 (2006.01)
CPC C07K 16/44 (2013.01) [G01N 33/66 (2013.01); C07K 2317/565 (2013.01)] 4 Claims
 
1. A monoclonal antibody or the antibody fragment thereof, wherein an amino acid sequence of a complementarity-determining region (CDR) 1 (CDR1) of a heavy chain variable region (VH) of the antibody or the antibody fragment thereof comprises the amino acid sequence set forth in SEQ ID NO:1, an amino acid sequence of CDR2 of the VH comprises the amino acid sequence set forth in SEQ ID NO:2, an amino acid sequence of CDR3 of the VH comprises the amino acid sequence set forth in SEQ ID NO:3, an amino acid sequence of CDR1 of a light chain variable region (VL) comprises the amino acid sequence set forth in SEQ ID NO:4, an amino acid sequence of CDR2 of the VL comprises the amino acid sequence set forth in SEQ ID NO:5, and an amino acid sequence of CDR3 of the VL comprises the amino acid sequence set forth in SEQ ID NO:6.